BioSim™ anti-Rituximab II (Human) ELISA Kit

Rituximab is a human/mouse chimeric monoclonal antibody that specifically targets CD20. CD20 is a B-cell differentiation marker that is expressed on pre- and mature B lymphocytes. Binding of the antibody to CD20 results in the destruction of B lymphocytes by one of the three potential mechanisms namely; apoptosis, antibody-dependent cytotoxicity, or complement-dependent cytotoxicity. The antibody has been approved to treat non-Hodgkin lymphoma, CD20+ B-cell malignancies, and rheumatoid arthritis. BioSim™ anti-Rituximab ELISA kit has been specifically developed to qualitatively determine antibodies to Rituximab in human serum and plasma samples. The ELISA kit is based on the sandwich principle. Controls and samples (serum and plasma) are incubated in the microtiter plate coated with the drug Rituximab. After incubation, the wells are washed and the enzymatic activity is detected by the addition of chromogen-substrate. The enzyme-substrate reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies specific for Rituximab present in the samples and controls. The qualitative test results can be evaluated using cut-off value.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the qualitative measurement of antibodies to Rituximab in human serum or plasma samples

Summary: N/A

Detection Method: Absorbance (450 nm)

Sample Type: Plasma,Serum

Species Reactivity: Human

Applications: A Sandwich ELISA kit for the qualitative measurement of antibodies to Rituximab in human serum or plasma samples

Features & Benefits: Assay Precision: Intra-Assay and Inter-Assay CV < 30%,Except for Rituximab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins,For in vitro qualitative determination of antibodies to Rituximab in human serum and plasma samples